Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.10
Percentage change -1.07	%

Peers: JNJ LLY MRNA PFE MRK REGN BNTX GILD NVAX VIR

| Held by: VXF IWC

Index	-	P/E	-	EPS (ttm)	-	Insider Own	69.92%	Shs Outstand	19.53M	Perf Week	-0.32%
Market Cap	180.85M	Forward P/E	-	EPS next Y	-	Insider Trans	11.48%	Shs Float	5.88M	Perf Month	16.33%
Income	-	PEG	-	EPS next Q	-	Inst Own	1.96%	Short Float	1.36%	Perf Quarter	13.90%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	10.79%	Short Ratio	1.42	Perf Half Y	-
Book/sh	0.27	P/B	33.75	EPS next Y	-	ROA	-	Short Interest	0.08M	Perf Year	-
Cash/sh	0.69	P/C	13.38	EPS next 5Y	-	ROE	-	52W Range	5.51 - 11.73	Perf YTD	16.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-21.06%	Beta	-
Dividend TTM	-	Quick Ratio	1.68	Sales past 5Y	0.00%	Gross Margin	-	52W Low	68.06%	ATR (14)	0.99
Dividend Ex-Date	-	Current Ratio	1.68	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	53.55	Volatility	10.56% 10.84%
Employees	-	Debt/Eq	0.07	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	20.00
Option/Short	No / Yes	LT Debt/Eq	0.07	EPS Q/Q	-8.10%	Payout	-	Rel Volume	0.18	Prev Close	9.36
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Nov 27	Avg Volume	56.47K	Price	9.26
SMA20	3.25%	SMA50	8.36%	SMA200	12.58%	Trades		Volume	9,906	Change	-1.07%

Jan-07-25 08:00AM	Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer (GlobeNewswire)
Dec-17-24 08:28AM	Actuate Therapeutics Announces Positive Interim Phase 2 Data of Elraglusib in First Line Treatment of Metastatic Pancreatic Cancer (GlobeNewswire) -11.85%
Nov-26-24 08:00AM	Actuate Therapeutics to be Added to Russell 2000 Index (GlobeNewswire)
Nov-12-24 08:00AM	Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma (GlobeNewswire)
Oct-29-24 06:39PM	Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development (GlobeNewswire)
08:00AM	Loading…
Sep-23-24 08:00AM	Actuate Announces Scientific Reports Publication on Elraglusib's Novel Immunomodulatory Mechanism of Action as a GSK-3 Inhibitor (GlobeNewswire) -8.89%
Sep-16-24 08:00AM	Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination with FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research (GlobeNewswire)
Sep-11-24 08:00AM	Actuate Receives FDA Orphan Drug Designation for Elraglusib for Treatment of Soft Tissue Sarcomas (GlobeNewswire)
Sep-09-24 08:00AM	Actuate Therapeutics Obtains Complete Responses and Provides Update on Clinical Trial of Elraglusib for the Treatment of Relapsed/Refractory Ewing Sarcoma (GlobeNewswire)
Sep-05-24 09:10AM	Actuate to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-20-24 09:00AM	Actuate Therapeutics to Ring the Nasdaq Opening Bell on Friday, August 23, 2024 (GlobeNewswire)
Aug-14-24 04:05PM	Actuate Therapeutics Announces Closing of Initial Public Offering (GlobeNewswire) +6.27%
Aug-12-24 08:27PM	Actuate Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)
May-28-24 07:00AM	Actuate Therapeutics Files Registration Statement for Initial Public Offering (GlobeNewswire)

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
THOMSON TODD S	16.4% Owner	Aug 14 '24	Sale	8.00	18,750	150,000	1,184,795	Aug 16 09:12 PM
Bios Equity COF, LP	Director	Aug 14 '24	Buy	8.00	500,000	4,000,000	1,259,427	Aug 14 08:54 PM
Bios Equity COF, LP	Director	Aug 14 '24	Sale	9.00	24,999	224,991	131,248	Aug 14 08:54 PM
Fletcher Aaron G.L.	Director	Aug 14 '24	Buy	8.00	500,000	4,000,000	1,259,427	Aug 14 08:49 PM
Fletcher Aaron G.L.	Director	Aug 14 '24	Sale	9.00	24,999	224,991	131,248	Aug 14 08:49 PM
Kreis Leslie W.	10% Owner	Aug 14 '24	Buy	8.00	500,000	4,000,000	1,259,427	Aug 14 08:44 PM
Kreis Leslie W.	10% Owner	Aug 14 '24	Sale	9.00	24,999	224,991	131,248	Aug 14 08:44 PM

Open in Screener

LTRN

Lantern Pharma Inc

Feb 04 • 04:00PM ET

4.80

Dollar change +0.13
Percentage change 2.78	%

Healthcare • Biotechnology • USA • NASD

LTRN Lantern Pharma Inc daily Stock Chart

Peers: EXAI DNLI FATE IMTX KRYS RAPT RPTX XERS ARDX

| Held by: VTI VXF MEDX IWC DFAT DFSU DFAC DXUV DCOR

Index	-	P/E	-	EPS (ttm)	-1.77	Insider Own	25.49%	Shs Outstand	10.78M	Perf Week	2.13%
Market Cap	51.77M	Forward P/E	-	EPS next Y	-1.74	Insider Trans	0.00%	Shs Float	8.04M	Perf Month	45.45%
Income	-19.09M	PEG	-	EPS next Q	-0.51	Inst Own	12.06%	Short Float	2.33%	Perf Quarter	53.60%
Sales	0.00M	P/S	-	EPS this Y	-30.27%	Inst Trans	-2.37%	Short Ratio	1.88	Perf Half Y	28.34%
Book/sh	2.47	P/B	1.95	EPS next Y	9.40%	ROA	-48.91%	Short Interest	0.19M	Perf Year	13.48%
Cash/sh	2.60	P/C	1.85	EPS next 5Y	8.13%	ROE	-53.03%	52W Range	2.79 - 11.99	Perf YTD	50.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-39.81%	ROI	-71.53%	52W High	-59.97%	Beta	1.60
Dividend TTM	-	Quick Ratio	8.31	Sales past 5Y	0.00%	Gross Margin	-	52W Low	72.04%	ATR (14)	0.55
Dividend Ex-Date	-	Current Ratio	8.31	EPS Y/Y TTM	-27.05%	Oper. Margin	-	RSI (14)	58.85	Volatility	11.06% 14.26%
Employees	21	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	20.50
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-43.75%	Payout	-	Rel Volume	0.52	Prev Close	4.67
Sales Surprise	-	EPS Surprise	25.00%	Sales Q/Q	-	Earnings	Nov 07 AMC	Avg Volume	99.66K	Price	4.80
SMA20	12.46%	SMA50	28.55%	SMA200	11.97%	Trades		Volume	51,328	Change	2.78%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-21	Initiated	H.C. Wainwright	Buy	$32

Jan-27-25 06:54PM	Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies (Insider Monkey) -15.00%
07:55AM	Lantern Pharma Unveils Innovative AI-Powered Module to Improve the Precision, Cost and Timelines of Antibody-Drug Conjugate (ADC) Development for Cancer (Business Wire)
Jan-17-25 01:29PM	Lantern Pharma Inc. (LTRN): AI-Driven Cancer Drug Development (Insider Monkey)
Dec-10-24 10:40AM	AI-Powered Cancer Solutions: Lantern Pharma (LTRN) Launches Phase 2 Trial in Taiwan (Insider Monkey)
Dec-09-24 12:21PM	Lantern Pharma starts dosing in Taiwan in non-smoker lung cancer trial (Clinical Trials Arena)
08:15AM	Loading…
08:15AM	Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients (Business Wire)
Dec-07-24 01:59AM	Lantern Pharma Inc. (LTRN) Receives Second FDA Fast Track Designation for LP-184 in Triple Negative Breast Cancer (Insider Monkey)
Dec-03-24 08:00AM	Lantern Pharma's Investigational Drug-Candidate, LP-184, Receives Second Fast Track Designation from FDA for Treatment of Triple Negative Breast Cancer (TNBC) (Business Wire)
Nov-26-24 08:45AM	Lantern Pharma and Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality (Business Wire)
08:45AM	Lantern Pharma & Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality (Business Wire)
Nov-19-24 08:00AM	Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients (Business Wire)
Nov-08-24 06:03PM	Lantern Pharma Inc (LTRN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com) +12.28% -8.59%
Nov-07-24 04:05PM	Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates (Business Wire)
Nov-05-24 08:00AM	Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board (Business Wire)
Oct-31-24 08:00AM	Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET (Business Wire)
08:45AM	Loading…
Oct-23-24 08:45AM	Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024 (Business Wire)
Oct-21-24 08:00AM	Lantern Pharma to Host & Participate in Two Public Webinars During October (Business Wire)
Oct-15-24 09:07AM	Lantern Pharmas Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA (Business Wire)
Oct-09-24 05:56PM	Lantern Pharma Inc (LTRN) Q2 2024 Earnings Call Highlights: Promising Clinical Trials and ... (GuruFocus.com)
Sep-23-24 08:00AM	Lantern Pharma Announces Three U.S. FDA Rare Pediatric Disease Designations Granted to LP-184 in Multiple Ultra Rare Childrens Cancers (Business Wire)
Aug-31-24 02:02PM	Lantern Pharma Inc. (LTRN): A Penny Stock That Will Make You a Millionaire (Insider Monkey)
Aug-08-24 04:01PM	Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates (Business Wire) -7.68%
Aug-07-24 09:31AM	Lantern Pharma Highlights Promising Preclinical Results of LP-184's Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024 (Business Wire) +12.26%
Aug-05-24 08:00AM	Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort (Business Wire) -5.88%
Aug-01-24 08:00AM	Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET (Business Wire)
Jul-10-24 08:30AM	Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184 (Business Wire)
Jun-12-24 07:30AM	Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284 (Business Wire)
May-23-24 11:51AM	Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates (PR Newswire)
May-09-24 04:02PM	Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.09% -9.54%
May-06-24 06:41AM	Lantern Pharma and Oregon partner to develop cancer treatment (Pharmaceutical Technology) +11.38%
04:37AM	Loading…
04:37AM	Lantern Pharma, Oregon Therapeutics Partner to Develop AI-Driven Cancer Drug Collaboration (MT Newswires)
03:00AM	Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 A Potent Inhibitor of Cancer Metabolism (Business Wire)
May-02-24 07:30AM	Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET (Business Wire)
May-01-24 06:00AM	3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace) +5.69%
Apr-24-24 08:00AM	Lantern Pharma Launches "Webinar Wednesdays" Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development (Business Wire) -6.76%
Apr-22-24 08:12AM	Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan (Business Wire) +7.12%
Apr-10-24 08:45AM	Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth (PR Newswire)
Mar-20-24 09:00AM	Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028 (GlobeNewswire) +17.49%
Mar-19-24 09:06AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2023 Earnings Call Transcript (Insider Monkey) -24.80%
Mar-18-24 08:53PM	LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023 (InvestorPlace) +14.48%
05:32PM	Lantern Pharma Inc Reports Progress and Financials for FY 2023 (GuruFocus.com)
04:02PM	Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights (Business Wire)
Mar-15-24 08:00AM	Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284 (Business Wire) +18.37%
Mar-11-24 07:30AM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET (Business Wire) -23.58%
Mar-07-24 06:17AM	11 Best Artificial Intelligence Stocks Under $20 According To Hedge Funds (Insider Monkey) +21.13%
Mar-05-24 08:01AM	Lantern To Participate in H.C Wainwright & Co.s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference (Business Wire) +5.95%
Mar-04-24 08:01AM	Lantern Pharma's A.I. Platform, RADR, Surpasses 60 Billion Data Points Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines (Business Wire) +9.40%
Feb-20-24 08:01AM	3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom (InvestorPlace)
Feb-15-24 08:01AM	Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers (Business Wire)
Jan-17-24 07:30AM	Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer (Business Wire)
Dec-13-23 08:05AM	The 3 Most Undervalued AI Penny Stocks to Buy in December (InvestorPlace)
Nov-30-23 08:00AM	FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL) (Business Wire)
Nov-10-23 11:31AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q3 2023 Earnings Call Transcript (Insider Monkey) -11.53%
Nov-08-23 06:43PM	Lantern Pharma Inc (LTRN) Reports Q3 2023 Financial Results and Provides Operational Updates (GuruFocus.com) +33.21%
04:01PM	Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights (Business Wire)
Nov-01-23 08:00AM	Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ET (Business Wire)
Oct-24-23 04:03PM	The 7 Most Undervalued AI Penny Stocks to Buy: October 2023 (InvestorPlace)
Oct-10-23 08:00AM	Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ET (Business Wire) +10.32%
Oct-03-23 08:00AM	Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma (Business Wire) -8.23%
Sep-29-23 07:40AM	LTRN: Spotlight on LP-184 & 284 (Zacks)
Sep-25-23 08:30AM	Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors (Business Wire)
Sep-18-23 09:00AM	Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkins Lymphomas (Business Wire)
Sep-14-23 09:09AM	The 3 Most Undervalued Machine Learning Stocks to Buy in September 2023 (InvestorPlace)
Aug-31-23 08:00AM	Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkins Lymphomas at the Society of Hematologic Oncology Annual Meeting (Business Wire)
Aug-28-23 05:32PM	3 AI Stocks That Still Trade Under $10 Per Share (InvestorPlace)
08:00AM	Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors (Business Wire)
Aug-23-23 06:00PM	The 3 Most Undervalued Machine Learning Stocks to Buy Now: August 2023 (InvestorPlace)
Aug-14-23 08:30AM	Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT (Business Wire)
Aug-10-23 08:37AM	LTRN: 2Q:23 Quarterly Update (Zacks Small Cap Research) +7.07%
Aug-09-23 04:01PM	Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights (Business Wire)
09:11AM	3 AI Penny Stocks With the Potential to Make Your Financial Dreams Come True (InvestorPlace)
Aug-08-23 03:06PM	3 AI Stocks Youll Regret Not Buying Soon (InvestorPlace)
Aug-02-23 12:45PM	RedChip Launches 'Small Stocks, Big Money' Podcast (ACCESSWIRE)
08:00AM	Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET (Business Wire)
Aug-01-23 07:30PM	3 AI Stocks to Buy Under $10 in August 2023 (InvestorPlace) +5.62%
Jul-30-23 02:45PM	7 AI Penny Stocks that Could Hit $5 Soon (InvestorPlace)
Jul-17-23 08:00AM	Lantern Pharma to Participate and Present at Multiple Upcoming Conferences (Business Wire)
Jun-26-23 08:30AM	Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkins Lymphomas (Business Wire)
Jun-12-23 08:30AM	Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors (Business Wire) +7.96%
Jun-08-23 09:00AM	Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University (Business Wire)
May-19-23 06:50AM	3 Penny Stocks to Buy as the AI Sector Transforms Every Industry in 2023 (InvestorPlace) +6.38%
May-17-23 08:00AM	Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET (Business Wire)
May-10-23 09:59AM	LTRN: First Harmonic Patient Dosed (Zacks Small Cap Research)
May-09-23 04:01PM	Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights (Business Wire) +5.66%
May-03-23 09:00AM	Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic Clinical Trial (PR Newswire) -6.05%
May-02-23 04:01PM	Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET (Business Wire)
07:30AM	Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound (Business Wire)
Apr-13-23 07:30AM	Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284 (Business Wire)
Mar-28-23 08:00AM	Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer (Business Wire)
Mar-24-23 07:15AM	Lantern Pharma Inc. (NASDAQ:LTRN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-22-23 11:50AM	We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate (Simply Wall St.)
11:45AM	LTRN: 2022 Financial and Operational Results (Zacks Small Cap Research)
Mar-21-23 04:01PM	Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars (Business Wire) -5.38%
12:11PM	Q4 2022 Lantern Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-20-23 04:01PM	Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights (Business Wire)
Mar-15-23 08:00AM	Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting (Business Wire)
Mar-13-23 08:00AM	Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET (Business Wire) +9.30%
06:16AM	Lantern Pharma said it had no exposure to SVB or Signature Bank, after stock plunged last week (MarketWatch)
06:00AM	Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank (Business Wire)
Mar-09-23 08:00AM	Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors (Business Wire)

Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fletcher Aaron G.L.	10% Owner	May 24 '24	Sale	6.33	20,000	126,600	57,467	May 28 04:30 PM
Fletcher Aaron G.L.	10% Owner	May 23 '24	Sale	6.25	10,000	62,500	59,326	May 28 04:30 PM
Fletcher Aaron G.L.	10% Owner	Feb 28 '24	Sale	4.85	74,297	360,340	62,088	Feb 29 09:54 PM
Fletcher Aaron G.L.	10% Owner	Feb 27 '24	Sale	4.40	50,000	220,000	68,997	Feb 29 09:54 PM
Fletcher Aaron G.L.	10% Owner	Feb 29 '24	Sale	4.87	19,703	95,954	60,256	Feb 29 09:54 PM
Kreis Leslie W.	10% Owner	Feb 28 '24	Sale	4.85	74,297	360,340	62,088	Feb 29 09:54 PM
Kreis Leslie W.	10% Owner	Feb 27 '24	Sale	4.40	50,000	220,000	68,997	Feb 29 09:54 PM
Kreis Leslie W.	10% Owner	Feb 29 '24	Sale	4.87	19,703	95,954	60,256	Feb 29 09:54 PM

Open in Screener

AZTR

Azitra Inc

Feb 04 • 04:00PM ET

0.3240

Dollar change +0.0455
Percentage change 16.34	%

Healthcare • Biotechnology • USA • AMEX

Peers: ANAB FATE VYGR AKTX CARA ARWR ORMP PULM ARMP BCRX

Index	-	P/E	-	EPS (ttm)	-13.36	Insider Own	1.60%	Shs Outstand	7.63M	Perf Week	7.64%
Market Cap	2.47M	Forward P/E	-	EPS next Y	-0.73	Insider Trans	0.00%	Shs Float	7.50M	Perf Month	-27.16%
Income	-9.03M	PEG	-	EPS next Q	-0.31	Inst Own	2.07%	Short Float	28.36%	Perf Quarter	-34.93%
Sales	0.10M	P/S	24.72	EPS this Y	96.27%	Inst Trans	-7.38%	Short Ratio	1.26	Perf Half Y	-50.98%
Book/sh	1.06	P/B	0.31	EPS next Y	64.39%	ROA	-104.57%	Short Interest	2.13M	Perf Year	-99.07%
Cash/sh	0.95	P/C	0.34	EPS next 5Y	-	ROE	-134.85%	52W Range	0.23 - 38.10	Perf YTD	-23.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-107.36%	52W High	-99.15%	Beta	-1.65
Dividend TTM	-	Quick Ratio	5.58	Sales past 5Y	149.87%	Gross Margin	-352.29%	52W Low	39.35%	ATR (14)	0.07
Dividend Ex-Date	-	Current Ratio	5.58	EPS Y/Y TTM	-	Oper. Margin	-11416.44%	RSI (14)	49.17	Volatility	36.68% 23.65%
Employees	10	Debt/Eq	0.08	Sales Y/Y TTM	-	Profit Margin	-9259.63%	Recom	1.00	Target Price	3.50
Option/Short	No / Yes	LT Debt/Eq	0.04	EPS Q/Q	96.40%	Payout	-	Rel Volume	146.36	Prev Close	0.28
Sales Surprise	-	EPS Surprise	59.04%	Sales Q/Q	-100.00%	Earnings	Nov 12 AMC	Avg Volume	1.69M	Price	0.32
SMA20	2.42%	SMA50	-19.48%	SMA200	-83.51%	Trades		Volume	247,703,293	Change	16.34%

Feb-04-25 02:20PM	Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock (PR Newswire) +16.34%
Feb-03-25 09:05AM	Azitra, Inc. to Present at the BIO CEO & Investor Conference (PR Newswire) +15.08%
Jan-27-25 04:05PM	Azitra, Inc. to Present at The Microcap Conference (PR Newswire) -6.64% +20.35%
Jan-15-25 08:30AM	Azitra Announces Pricing of $1.5 Million Public Offering of Common Stock (PR Newswire) -39.03%
Jan-14-25 04:05PM	Azitra Announces Proposed Public Offering of Common Stock (PR Newswire) -26.75%
05:05PM	Loading…
Nov-12-24 05:05PM	Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates (PR Newswire)
Oct-29-24 09:00AM	Azitra to Present at BIO-Europe 2024 (Business Wire)
Oct-11-24 09:00AM	Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit (Business Wire)
Sep-24-24 08:00AM	Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress (Business Wire)
Sep-18-24 09:00AM	Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors (Business Wire) +5.82%
Sep-06-24 04:30PM	Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-28-24 08:30AM	Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome (Business Wire)
Aug-22-24 09:00AM	Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors (Business Wire) +11.14%
Aug-20-24 04:15PM	Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome (Business Wire) +5.98%
Aug-12-24 06:23PM	Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates (Business Wire)
05:57PM	Loading…
Jul-25-24 05:57PM	CORRECTING and REPLACING Azitra, Inc. Announces Closing of $10.0 Million Public Offering (Business Wire) -9.65%
Jul-23-24 09:20PM	Azitra, Inc. Announces Pricing of $10.0 Million Public Offering (Business Wire) +206.79% -76.46%
08:00AM	Azitra, Inc. Strengthens Global Intellectual Property Portfolio with Newly Granted and Allowed Patents (Business Wire)
Jun-27-24 04:05PM	Azitra, Inc. Announces Reverse Stock Split (Business Wire) +12.72% -30.15%
May-31-24 08:00AM	Azitra, Inc. Announces Presentation at the 2024 BIO International Convention (Business Wire)
May-17-24 08:00AM	Azitra, Inc. Announces Positive Preclinical Data from ATR-04 Presented at the Society of Investigative Dermatology Annual Meeting (Business Wire) -8.22%
May-10-24 08:00AM	Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting (Business Wire) -13.08%
May-09-24 05:00PM	Azitra, Inc. Announces Q1 2024 Financial Results and Provides Business Updates (Business Wire)
Apr-22-24 04:30PM	Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting (Business Wire) +18.77%
Apr-18-24 04:15PM	Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024 (Business Wire) -5.10%
Mar-15-24 04:15PM	Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates (Business Wire)
Feb-16-24 04:05PM	Azitra, Inc. Announces Closing of Public Offering (Business Wire) +6.01% +5.79%
Feb-13-24 10:09PM	Azitra, Inc. Announces Pricing of Public Offering (Business Wire) -24.33% -73.91%
Jan-16-24 09:00AM	Azitra, Inc. Strengthens Intellectual Property Portfolio with Newly Granted Patent in the US (Business Wire) +32.50%
Jan-03-24 09:00AM	Azitra, Inc. to Present at Biotech Showcase 2024 and the Dermatology Summit 2024, Alongside the J.P. Morgan Annual Healthcare Conference (Business Wire) +11.42%
04:30PM	Loading…
Nov-14-23 04:30PM	Azitra, Inc. Announces Third Quarter 2023 Financial Results and Business Updates (Business Wire)
Oct-16-23 08:00AM	Azitra to Present at the ThinkEquity Conference (Business Wire) +7.59%
Aug-29-23 08:00AM	Azitra to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-14-23 04:05PM	Azitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates (PR Newswire) -6.52%
Jul-19-23 04:05PM	Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors (PR Newswire)
Jul-11-23 04:05PM	Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer (PR Newswire)
Jun-21-23 06:46PM	Azitra, Inc. Announces Closing of Initial Public Offering (PR Newswire) +9.62%
Jun-15-23 07:04PM	Azitra, Inc. Announces Pricing of Initial Public Offering (PR Newswire)

Azitra, Inc. is an early-stage clinical biopharmaceutical company, which engages in the development of therapeutic use in dermatology. The firm is involved in using engineered proteins and live bio therapeutic products that can be applied topically to treat diseases of the skin. It also offers a platform which is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen library of strains for drug like molecules. The company was founded by Azim Munivar and Travis Whitfill on January 2, 2014 and is headquartered in Branford, CT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KDT VENTURES FUND I, LP	Former Director	Sep 13 '24	Proposed Sale	0.58	9,730	5,648		Sep 16 05:47 PM
Staskey Norm	Chief Financial Officer	Mar 29 '24	Buy	0.21	47,600	10,034	51,100	Apr 01 09:51 PM
Whitfill Travis	Chief Operating Officer	Feb 13 '24	Buy	0.30	15,000	4,500	334,500	Feb 15 08:42 PM
Staskey Norm	Chief Financial Officer	Feb 13 '24	Buy	0.30	3,300	990	3,500	Feb 15 08:39 PM
Salva Francisco D.	President and CEO	Feb 13 '24	Buy	0.30	333,300	99,990	338,300	Feb 15 08:38 PM

ACTU

Actuate Therapeutics Inc

LTRN

Lantern Pharma Inc

AZTR

Azitra Inc

ACTU

Actuate Therapeutics Inc

LTRN

Lantern Pharma Inc

AZTR

Azitra Inc

Upgrade your FINVIZ experience